These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 11846327

  • 1. Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women.
    Tsai KS, Yen ML, Pan HA, Wu MH, Cheng WC, Hsu SH, Yen BL, Huang KE.
    Osteoporos Int; 2001 Dec; 12(12):1020-5. PubMed ID: 11846327
    [Abstract] [Full Text] [Related]

  • 2. [A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women].
    Zheng SR, Wu YY, Zhang ZL, Yang X, Hui Y, Zhang Y, Chen SL, Den WH, Liu H, Ekangaki A, Stocks J, Harper K, Liu JL.
    Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):226-9. PubMed ID: 12885371
    [Abstract] [Full Text] [Related]

  • 3. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing.
    Zheng S, Wu Y, Zhang Z, Yang X, Hui Y, Zhang Y, Chen S, Deng W, Liu H, Ekangaki A, Stocks J, Harper K, Liu J.
    Chin Med J (Engl); 2003 Aug; 116(8):1127-33. PubMed ID: 12935394
    [Abstract] [Full Text] [Related]

  • 4. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.
    Reid IR, Eastell R, Fogelman I, Adachi JD, Rosen A, Netelenbos C, Watts NB, Seeman E, Ciaccia AV, Draper MW.
    Arch Intern Med; 2004 Apr 26; 164(8):871-9. PubMed ID: 15111373
    [Abstract] [Full Text] [Related]

  • 5. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harpe K.
    Zhonghua Yi Xue Za Zhi; 2004 Feb 17; 84(4):269-73. PubMed ID: 15059505
    [Abstract] [Full Text] [Related]

  • 6. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE, Bjarnason NH, Neven P, Plouffe L, Johnston CC, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW.
    Menopause; 2003 Feb 17; 10(4):337-44. PubMed ID: 12851517
    [Abstract] [Full Text] [Related]

  • 7. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL, He JW, Qin YJ, Huang QR, Liu YJ, Hu YQ, Li M.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr 17; 23(2):129-33. PubMed ID: 16604479
    [Abstract] [Full Text] [Related]

  • 8. Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women.
    Vogelvang TE, Mijatovic V, van der Mooren MJ, Pinsdorf U, von Bergmann K, Netelenbos JC, Lütjohann D.
    Maturitas; 2005 Apr 11; 50(4):312-20. PubMed ID: 15780532
    [Abstract] [Full Text] [Related]

  • 9. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.
    Gol M, Akan P, Dogan E, Karas C, Saygili U, Posaci C.
    Maturitas; 2006 Feb 20; 53(3):252-9. PubMed ID: 15990257
    [Abstract] [Full Text] [Related]

  • 10. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women.
    Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH.
    JAMA; 2006 Feb 20; 287(20):2668-76. PubMed ID: 12020302
    [Abstract] [Full Text] [Related]

  • 11. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
    Dias AR, Melo RN, Gebara OC, D'Amico EA, Nussbacher A, Halbe HW, Pinotti JA.
    Climacteric; 2005 Mar 20; 8(1):63-70. PubMed ID: 15804733
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women.
    Anderson PW, Cox DA, Sashegyi A, Paul S, Silfen SL, Walsh BW.
    Maturitas; 2001 Jul 25; 39(1):71-7. PubMed ID: 11451623
    [Abstract] [Full Text] [Related]

  • 14. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
    Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C.
    N Engl J Med; 1997 Dec 04; 337(23):1641-7. PubMed ID: 9385122
    [Abstract] [Full Text] [Related]

  • 15. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.
    JAMA; 1996 Nov 06; 276(17):1389-96. PubMed ID: 8892713
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C, Dane B, Cetin A, Erginbas M.
    Gynecol Endocrinol; 2007 Jul 06; 23(7):398-403. PubMed ID: 17701771
    [Abstract] [Full Text] [Related]

  • 17. Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study.
    O'Neill SM, Eden J, Baber R, Ekangaki A, Stocks JM, Wolthers T, Davis SR.
    Climacteric; 2003 Dec 06; 6(4):347-53. PubMed ID: 15006256
    [Abstract] [Full Text] [Related]

  • 18. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
    Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper MW.
    Osteoporos Int; 1999 Dec 06; 10(4):330-6. PubMed ID: 10692984
    [Abstract] [Full Text] [Related]

  • 19. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
    Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ.
    N Engl J Med; 1998 Feb 19; 338(8):485-92. PubMed ID: 9443925
    [Abstract] [Full Text] [Related]

  • 20. Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women.
    Vogelvang TE, Leurs JR, van der Mooren MJ, Mijatovic V, Hendriks DF, Neele SJ, Netelenbos JC, Kenemans P.
    Menopause; 2004 Feb 19; 11(1):110-5. PubMed ID: 14716191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.